Please ensure Javascript is enabled for purposes of website accessibility

Why Quidel Stock Soared 42% in April

By Beth McKenna – Updated May 5, 2020 at 11:03AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This coronavirus testing company's stock is on fire.

What happened

Shares of Quidel (QDEL), which makes diagnostic healthcare products, skyrocketed 42.1% in April, according to data from S&P Global Market Intelligence. That follows its robust performance in March, when it gained 26.6%.

For context, the S&P 500 index returned 12.8% last month after returning negative 12.4% in March due to the coronavirus-driven market sell-off.

A gloved hand holding a vial of blood labeled "coronavirus" with "no" checked (instead of "yes")

Image source: Getty Images.

So what

Quidel stock got a tailwind from the strength of the overall market last month. The reason it significantly outperformed the market is because investors are excited about the sales prospects for the company's rapid COVID-19 test.

Shares moved up throughout the month. But they got a big boost -- of 9.5% -- following Quidel's Feb. 22 announcement that it had applied for an emergency use authorization (EUA) for an upgraded test, the Lyra Direct SARS-CoV-2 Assay, from the Food and Drug Administration (FDA) to allow direct sample processing. In that same press release, the company said it was currently manufacturing 500,000 tests per week, saying that the "assay is currently available for sale in the United States while under EUA review." 

In mid-March, the company received emergency use authorization from the FDA to market its Lyra SARS-CoV-2 Assay. And later that month, its test received the CE Mark, which means it can be marketed in Europe, and the green light from Health Canada. 

Now what

Investors will soon get material news. Quidel is scheduled to report its first-quarter 2020 results on Wednesday, May 6, after the market close. 

Beth McKenna has no position in any of the stocks mentioned. The Motley Fool recommends Quidel. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Quidel Stock Quote

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.